Traditional targeted drug discovery approaches have identified FXR and PPAR agonists converging on this broader family of nuclear receptors intimately associated with NAFLD pathophysiology. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.